Etern has made tremendous progress to prove that targeting LLPS is a feasible strategy for drug development, especially for “undruggable” targets.
Each project is independently developed and stemmed from high-impact paper published by Etern. The strong research and development capabilities have laid a solid foundation for successful development of LLPS inhibitors.